The development of immunotherapy over the last 10 years has led to the emergence of numerous predictive immune biomarkers like PD1 and PDL-1 expression, mutational tumor burden (TMB), and tumor-infiltrating lymphocytes (TIL). Here, CD274 is linked to neoplasm.